세계 유전자 패널 시장 규모는 2024년에 29억 8,000만 달러로 평가되었고, 예측 기간 중 CAGR은 7.45%를 나타낼 전망이며, 2030년에는 45억 5,000만 달러에 달할 것으로 예측되고 있습니다.
세계의 유전자 패널 시장은 다양한 질병의 조기 진단·치료에 있어서의 유전자 검사의 중요성이 커지면서 견고한 확장세를 보이고 있습니다. 여러 유전자를 동시에 분석할 수 있는 유전자 패널은 종양학, 희귀질환 검출, 약리 유전체학의 분야에서 요점이 되고 있습니다. 맞춤형 의료나 표적 치료로의 전환은 특히 유전성 암 리스크 평가, 선천성 질환, 신경 질환에 대한 유전자 패널 검사의 채택을 크게 뒷받침하고 있습니다. 차세대 시퀀싱(NGS)의 기술적 진보는 유전자 변이체의 분석을 보다 빠르고, 정확하며 비용 효율적으로 수행할 수 있게 하며, 이 성장에 있어 매우 중요합니다. 앰플리콘 기반 및 하이브리드 캡처 기반 기술을 통해 연구자와 임상의는 특정 임상 요구 사항에 따라 유전자 패널을 사용자 정의할 수 있게 되었습니다. 예를 들어, 2023년 10월, 중국 국가 의약품 감독 관리국(NMPA)은 비소세포 폐암(NSCLC)에 대한 Geneseeq의 종양 변이 부하 검사 키트를 승인했습니다. 이 키트는 425개의 암 관련 유전자를 포괄하는 종합적인 유전자 패널을 특징으로 하며, 폐암 환자의 보다 정확한 진단과 치료 계획을 지원함으로써 정밀 종양학을 강화하는 것을 목표로 하고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 29억 8,000만 달러 |
| 시장 규모 : 2030년 | 45억 5,000만 달러 |
| CAGR 2025-2030년 | 7.45% |
| 급성장 부문 | 병원 및 진단실 |
| 최대 시장 | 북미 |
시퀀싱 기술의 저가격화와 환자 및 의료 종사자의 의식이 높아짐에 따라, 선진국과 신흥국을 불문하고 유전자 패널 시장 침투가 가속하고 있습니다. 유방암, 대장암, 난소암 등에서는 치료방침의 결정에 다유전자 패널이 빈번하게 사용되게 되었습니다.
유전성 질환 및 만성 질환의 발병률 증가
검사 및 장비의 높은 비용
인공지능과 머신러닝의 통합
Global Gene Panel Market was valued at USD 2.98 billion in 2024 and is expected to reach USD 4.55 billion by 2030 with a CAGR of 7.45% during the forecast period. The global gene panel market is witnessing robust expansion, driven by the growing importance of genetic testing in the early diagnosis and treatment of various diseases. Gene panels, which allow simultaneous analysis of multiple genes, have become a cornerstone in the fields of oncology, rare disease detection, and pharmacogenomics. The shift toward personalized medicine and targeted therapies has significantly boosted the adoption of gene panel testing, especially for hereditary cancer risk assessment, congenital disorders, and neurological diseases. Technological advancements in next-generation sequencing (NGS) have been pivotal in this growth, enabling faster, more accurate, and cost-effective analysis of gene variants. Amplicon-based and hybrid-capture based techniques have made it easier for researchers and clinicians to customize gene panels according to specific clinical requirements. For instance, in October 2023, China's National Medical Products Administration (NMPA) approved Geneseeq's tumor mutational burden test kit for non-small cell lung cancer (NSCLC). The kit features a comprehensive gene panel covering 425 cancer-related genes, aiming to enhance precision oncology by supporting more accurate diagnosis and treatment planning in lung cancer patients.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 2.98 Billion |
| Market Size 2030 | USD 4.55 Billion |
| CAGR 2025-2030 | 7.45% |
| Fastest Growing Segment | Hospital & Diagnostic Laboratories |
| Largest Market | North America |
The decreasing cost of sequencing technologies and growing awareness among patients and healthcare providers are accelerating the market penetration of gene panels across both developed and emerging economies. Healthcare systems around the world are increasingly incorporating genetic information into clinical workflows, particularly for cancer diagnostics. Multigene panels are now frequently used to guide treatment decisions in breast, colorectal, and ovarian cancers. Beyond oncology, gene panels are also gaining traction in cardiology, infectious diseases, and prenatal testing, widening their scope of applications.
Key Market Drivers
Rising Incidence of Genetic and Chronic Diseases
The rising incidence of genetic and chronic diseases is a major driver propelling the growth of the global gene panel market. For instance, according to the Genetic and Rare Disease (GARD) Information Center, over 7,000 genetic conditions have been identified, with the number steadily increasing. In the U.S., at least 200,000 individuals live with known genetic disorders, while in the U.K., around 30,000 infants are diagnosed annually, contributing to over 2.4 million survivors. Gene panels are often developed to detect such conditions at birth, enabling timely diagnosis and early intervention through appropriate treatment and management strategies. This early detection plays a crucial role in improving patient outcomes and reducing the long-term burden of genetic diseases. Over the past decade, there has been a significant increase in the prevalence of genetic disorders such as cystic fibrosis, thalassemia, and sickle cell anemia, as well as complex chronic conditions like cancer, cardiovascular diseases, and neurodegenerative disorders. Many of these diseases have a strong genetic component, making early and accurate detection through gene panels a critical aspect of modern diagnostics. Gene panels allow clinicians to analyze multiple genes simultaneously to identify mutations associated with hereditary conditions, enabling timely intervention and better disease management. Cancer, in particular, has seen an alarming rise worldwide, with a growing emphasis on personalized treatment approaches based on individual genetic profiles. Gene panel testing has become an essential tool in oncology, helping to detect germline and somatic mutations that influence cancer susceptibility and treatment response. For instance, BRCA1 and BRCA2 gene panels are widely used to assess the risk of breast and ovarian cancers, guiding both preventive strategies and therapeutic choices. Similarly, chronic illnesses such as diabetes, Alzheimer's disease, and cardiovascular disorders often have underlying genetic factors that can be identified through targeted panels, allowing for more precise risk stratification and personalized care plans.
Key Market Challenges
High Cost of Testing and Equipment
The high cost of advanced filtration systems presents a significant challenge to the global gene panel market. As laboratories increasingly demand high-performance solutions for applications in pharmaceuticals, biotechnology, environmental testing, and academic research, the complexity and technological sophistication of filtration equipment have grown. However, this advancement comes at a cost-systems such as nanofiltration, ultrafiltration, and automated filtration setups require substantial capital investment. For many small- to medium-sized laboratories, especially in developing regions, these costs can be prohibitive. Beyond initial acquisition, ongoing operational expenses further burden end users. Advanced filtration systems often require specialized membranes, maintenance kits, calibration, and sometimes custom configurations to suit specific applications. The need for compatibility with other lab infrastructure or integration into automated workflows can increase the total cost of ownership. In sectors where funding is limited or subject to fluctuations, such as academic or public health labs, high-cost systems may be considered an unjustifiable expenditure, leading to reliance on outdated or less efficient alternatives.
Key Market Trends
Integration of Artificial Intelligence and Machine Learning
The integration of Artificial Intelligence (AI) and Machine Learning (ML) into the global gene panel market is rapidly transforming the landscape of genetic testing and precision medicine. AI and ML technologies enhance the ability to analyze vast amounts of genomic data quickly and accurately, addressing one of the key challenges in gene panel testing-interpreting complex genetic variations and identifying clinically relevant mutations. By leveraging sophisticated algorithms, AI can detect subtle patterns and correlations within genetic datasets that may be missed by traditional methods, leading to improved diagnostic accuracy and personalized treatment recommendations.
In gene panel testing, AI-driven tools are increasingly used for variant classification, predicting pathogenicity, and prioritizing genetic mutations for clinical relevance. Machine learning models trained on large genomic databases help in distinguishing benign variants from those linked to disease, reducing the number of variants of unknown significance (VUS) and enhancing the clinical utility of gene panels. This capability is particularly valuable in oncology, where identifying actionable mutations can guide targeted therapies and immunotherapies, improving patient outcomes. AI and ML enable automation of data processing pipelines, decreasing turnaround times and operational costs, which makes gene panel testing more accessible and scalable. The combination of AI with next-generation sequencing (NGS) platforms has led to the development of comprehensive cancer profiling assays that integrate genomic and epigenomic data, providing a more holistic view of tumor biology. For example, companies like Guardant Health use AI-powered liquid biopsy tests that non-invasively profile cancer-related genetic changes from blood samples, demonstrating the potential for less invasive and more frequent monitoring.
In this report, the Global Gene Panel Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Gene Panel Market.
Global Gene Panel Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report: